Search Results

You are looking at 1 - 10 of 30 items for :

  • somatostatin receptor ligand x
  • Refine by Access: All content x
Clear All
Open access

Marta Araujo-Castro, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Eider Pascual-Corrales, and Víctor Rodríguez Berrocal

, tumor consistency was reported to be an important predictive factor since hard consistency could impede transsphenoidal resection, especially in macroadenomas ( 8 ). Preoperative somatostatin receptor ligands (SRLs) treatment is proven to reduce GH and

Open access

Erik Rösner, Daniel Kaemmerer, Elisa Neubauer, Jörg Sänger, and Amelie Lupp

-8) for 16 min at 600 W and incubated with primary anti-PD-L1 antibody overnight at 4°C. To stain somatostatin receptors (SST) 1, 2, 3, 4, and 5, CXC motif chemokine receptor 4 (CXCR4), chromogranin A (CgA), and the proliferation marker Ki-67, the same

Open access

Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson

pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin

Open access

Sara Storvall, Helena Leijon, Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Camilla Schalin-Jäntti, and Johanna Arola

scarce. Ligand binding to somatostatin receptors induces receptor internalization by endocytosis for the lysosomal regrading or recycling of the receptor to the plasma membrane ( 36 , 37 ). This could represent one mechanism explaining the cytoplasmic

Open access

Bernardo Maia, Leandro Kasuki, and Mônica R Gadelha

patients have clinical contraindications or refuse to be submitted to surgery ( 4 , 10 ). Currently, there are three classes available for the treatment of acromegaly: somatostatin receptor ligands (SRLs), dopamine agonists, and GH receptor antagonist ( 4

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

Ferone D . Somatostatin receptor ligands in the treatment of acromegaly . Pituitary 2017 20 100 – 108 . ( ) 10.1007/s11102-017-0791-0 28176162 17 Körner M Waser B Christ E Beck J Reubi JC . A critical

Open access

Stefan Schulz, Anika Mann, Benjamin Novakhov, Hugh D Piggins, and Amelie Lupp

Introduction The overexpression of receptors for small regulatory peptides, e.g. somatostatin, bombesin, vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase-activating peptide (PACAP) provides the opportunity for effective clinical

Open access

Carolina Inda, Natalia G Armando, Paula A dos Santos Claro, and Susana Silberstein

). Colored arrows show ligand-receptor interactions, with gray arrows indicating lower affinity. CRH binds to both receptors but with higher affinity to CRHR1. UCN1 is a high affinity ligand to both CRHR1 and CRHR2, whereas UCN2 and UCN3 are considered

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, and S Cannavò

-018-0865-7 ) 29344905 10.1007/s11102-018-0865-7 21 Cuevas-Ramos D Fleseriu M . Somatostatin receptor ligands and resistance to treatment in pituitary adenomas . Journal of Molecular Endocrinology 2014 52 R223 – R240 . ( ) 10

Open access

Giovanni Tulipano

JP Wester HJ , International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature . Pharmacological Reviews 2018 763 – 835 . ( ) 50